Revolver Therapeutics raises £600k in funding led by QantX to develop peptides that shut down cancer-driving proteins

Revolver Therapeutics develops peptide-based therapeutics designed to inhibit transcription factors, proteins inside cancer cells that drive tumour growth, survival and treatment resistance. Its Transcription Block Survival platform identifies cell-penetrating peptides that can switch off these targets, which have traditionally been considered too difficult to reach with conventional drugs.